Press release
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market, Clinical Trials, Companies, Therapies, Therapies, Treatment, Pipeline Analysis | Pfizer, Spark Therapeutics, REGENXBIO
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market
DelveInsight reports that several leading companies are actively advancing therapeutic development efforts for Neuronal Ceroid-Lipofuscinoses (CLN1 disease).
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Overview:
Neuronal Ceroid-Lipofuscinoses (NCLs), including CLN1 disease, are rare inherited neurodegenerative conditions. CLN1, also referred to as Infantile NCL (INCL) or the CLN1 subtype of Batten disease, arises from mutations in the PPT1 (palmitoyl-protein thioesterase 1) gene. These mutations cause the buildup of lipopigments (lipofuscin) within neurons and other cells, ultimately leading to progressive neurological deterioration.
Request for a detailed insights report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights [https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
DelveInsight's "Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease), historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Key Takeaways from the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Report
*
DelveInsight's Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report highlights a dynamic landscape with several key players actively pursuing novel therapies for CLN1 disease.
*
Leading companies such as Pfizer, Spark Therapeutics, REGENXBIO, and others are investigating innovative drug candidates aimed at improving treatment outcomes.
*
In May 2019, Abeona Therapeutics secured FDA approval for its IND application to launch a Phase 1/2 clinical trial of ABO-202, an AAV9-based gene therapy developed to deliver a functional PPT1 gene to the central nervous system and peripheral organs. Subsequently, in June 2019, the FDA granted Fast Track designation to ABO-202, acknowledging its potential to meet significant unmet needs in CLN1 disease management.
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Analysis
The report provides insights into:
*
The report provides detailed insights into the key companies that are developing therapies in the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market.
*
The report also evaluates different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment.
*
It analyzes the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
It navigates the emerging drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement, and financing details for future advancement of the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market.
Download our free sample page report on Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline insights [https://www.delveinsight.com/sample-request/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Companies
Several leading companies, including Pfizer, Spark Therapeutics, REGENXBIO, and others, are actively engaged in developing therapies for Neuronal Ceroid-Lipofuscinoses (CLN1 disease) (CRPS).
DelveInsight's report covers around 3+ products under different phases of clinical development like
*
Late stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I) along with the details of
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapies and Key Companies: Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Clinical Trials and advancements [https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Therapeutic Assessment
- Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Product Type
- Neuronal Ceroid-Lipofuscinoses (CLN1 disease) By Stage
- Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Route of Administration
- Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Assessment by Molecule Type
Download Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Sample report to know in detail about the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment market @ Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Therapeutic Assessment [https://www.delveinsight.com/sample-request/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Current Treatment Patterns
4. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Late-Stage Products (Phase-III)
7. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Discontinued Products
13. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Product Profiles
14. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Companies
15. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Key Products
16. Dormant and Discontinued Products
17. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Unmet Needs
18. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Future Perspectives
19. Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline Reports Offerings [https://www.delveinsight.com/report-store/neuronal-ceroid-lipofuscinoses-cln1-disease-market?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuronal-ceroidlipofuscinoses-cln1-disease-market-clinical-trials-companies-therapies-therapies-treatment-pipeline-analysis-pfizer-spark-therapeutics-regenxbio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market, Clinical Trials, Companies, Therapies, Therapies, Treatment, Pipeline Analysis | Pfizer, Spark Therapeutics, REGENXBIO here
News-ID: 4158959 • Views: …
More Releases from ABNewswire
Hillman Unveils New-Generation Hunting Boots for Men Featuring Dual-Insulation a …
Image: https://www.abnewswire.com/upload/2025/09/ba5edccf338bc4d7305201efbc60a77a.jpg
Hillman, the performance hunting brand trusted by professionals across rugged North American terrain, today announced the release of its next-generation line of hunting boots for men [https://hillmangear.com/collections/hunting-boots-men-s-hunt-footwear], engineered with a dual-insulation system inspired by space technology. The new hunting boots collection features NASA-developed Aerogel Trademark paired with Matrix Registered insulation to deliver arctic-level warmth at a fraction of the weight and bulk of traditional padded boots.
Purpose-built for early season…
Cedric D. Fisher & Company Publishers Releases SIGHT: Groundbreaking Novel Explo …
Cedric D. Fisher & Company Publishers launches SIGHT by Alexandria Clarimond, a literary fiction novel following Elora ("Ellie") through seven decades of life as she confronts progressive blindness from macular degeneration. The novel's innovative "Seven Sight Loss Events" structure parallels physical vision decline with spiritual awakening, creating a powerful meditation on resilience and meaning.
SAN ANTONIO, TX - September 18th, 2025 - Cedric D. Fisher & Company Publishers, a San Antonio-based…
New Launch Protech Systems - A Security System Installation Company in Vancouver …
Protech Systems, a newly launched security system installation company in Vancouver, BC, is now open to serve homeowners and businesses. The company specializes in installing and integrating advanced security solutions, including alarm systems, security cameras, smart home integrations, and monitoring services.
Vancouver, BC - Protech Systems has officially launched in Vancouver, British Columbia, bringing modern home and commercial security solutions to families and business owners across the Lower Mainland. With over…
Soft Tissue Sarcoma Market to Experience Notable Growth in Forecast Span by 2034 …
The Key Soft Tissue Sarcoma Companies in the market include - Epizyme, Blueprint Medicines, Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, and others.
The Soft Tissue Sarcoma market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period.…
More Releases for CLN1
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market, Clinical and Non-Clinical …
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Pipeline constitutes key companies continuously working towards developing Neuronal Ceroid-Lipofuscinoses (CLN1 disease) treatment therapies, analyzes DelveInsight.
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Overview:
Neuronal Ceroid-Lipofuscinoses (NCLs), including CLN1 disease, are a group of rare, inherited neurodegenerative disorders. CLN1 disease, also known as Infantile NCL (INCL) or Batten disease (CLN1 subtype), is caused by mutations in the PPT1 (palmitoyl-protein thioesterase 1) gene. This leads to the accumulation of lipopigments (lipofuscin) in…
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market to Witness Growth by 2032, …
DelveInsight's "Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Neuronal Ceroid-Lipofuscinoses (CLN1 disease), historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market to Witness Growth by 2032, …
DelveInsight's "Neuronal Ceroid-Lipofuscinoses (CLN1 disease) Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of Neuronal Ceroid-Lipofuscinoses (CLN1 disease), historical and forecasted epidemiology as well as the Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
The Neuronal Ceroid-Lipofuscinoses (CLN1 disease) market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and…
Neuronal Ceroid Lipofuscinoses Cln1 Market - Illuminating Paths to Hope: Breakth …
Newark, New Castle, USA: The "Neuronal Ceroid Lipofuscinoses Cln1 Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Neuronal Ceroid Lipofuscinoses Cln1 Market: https://www.growthplusreports.com/report/neuronal-ceroid-lipofuscinoses-cln1-market/8680
This latest report researches the…
Neuronal Ceroid Lipofuscinoses Cln1 Market Insights, Forecast to 2031
The report extensively examines the global Neuronal Ceroid Lipofuscinoses Cln1 market while focusing on the leading companies and their business strategies, geographical growth, market segmentation, competitive environment, production, price, and cost structures. Each section of the research report has been carefully designed to examine important facets of the global market for Neuronal Ceroid Lipofuscinoses Cln1 . For instance, the market dynamics section delves deeply into the trends, opportunities, and drivers…
Neuronal Ceroid Lipofuscinoses Cln1 Market Statistical Forecast, Trade Analysis …
Newark, New Castle, USA - The latest report from Growth Plus Reports analyzes the production, potential applications, demand, major manufacturers, and SWOT analysis of the global Neuronal Ceroid Lipofuscinoses Cln1 Market.
The Neuronal Ceroid Lipofuscinoses Cln1 Market Report assists in determining the optimum distribution methods for certain products as well as possible markets for future product launches. The report also analyses the purchase and supply trends that influence the market's production…
